Trial
NCT02138812
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Medical Oncology
Intervention
BAY1161909
Why stopped
As another Mps1 inhibitor was being developed in parallel, the strategic decision was to move forward with the development of the follow up compound only.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-12